CHRS supply chain intelligence for Coherus Oncology, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| JUNSHI-BIOSCIENCES | JUNSHI-BIOSCIENCES | 92% | We are obligated to pay Junshi Biosciences a royalty in the low twenty percent range on net sales of LOQTORZI and up to an aggregate $380.0 million in one-time payments for the achievement of various… |
| AMRX | Amneal Pharmaceuticals, Inc. | 72% | plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel… |
| AMRX | Amneal Pharmaceuticals, Inc. | 72% | Reciprocal relationship from AMRX graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions r… |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions re… |
| AZN | AstraZeneca PLC | 72% | plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from BMY graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from BMY grap… |
| BMY | Bristol-Myers Squibb Company | 72% | plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions … |
| BMYMP | Bristol-Myers Squibb Co | 72% | plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel… |
| FMS | Fresenius Medical Care AG | 72% | Reciprocal relationship from FMS graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions re… |
| FMS | Fresenius Medical Care AG | 72% | plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel… |
| GILD | Gilead Sciences, Inc. | 72% | plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions r… |
| MRK | Merck & Co., Inc. | 72% | plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions re… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions r… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CAH | Cardinal Health, Inc. | 95% | e employees, effective March 10, 2023 for most of these employees. In the first quarter of 2023, non-recurring restructuring charges associated with the reduction in force consisted of $ million in c… |
| CAH | Cardinal Health, Inc. | 95% | Reciprocal relationship from CAH graph: Reciprocal relationship from CHRS graph: e employees, effective March 10, 2023 for most of these employees. In the first quarter of 2023, non-recurring restruc… |
| MCK | McKesson Corporation | 95% | Reciprocal relationship from MCK graph: Reciprocal relationship from CHRS graph: revenue was generated in the United States. The Company’s net revenue was as follows: … |
| MCK | McKesson Corporation | 95% | revenue was generated in the United States. The Company’s net revenue was as follows: Year Ended December 31, (in thousands) 2025 2024 LOQTORZI $ 40,836 $ … |
| APOTEX | APOTEX | 90% | we granted to Apotex an exclusive license under our rights to toripalimab to commercialize toripalimab within Canada |
| AMRX | Amneal Pharmaceuticals, Inc. | 72% | Reciprocal relationship from AMRX graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from AMRX graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers … |
| AMRX | Amneal Pharmaceuticals, Inc. | 72% | plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel… |
| AZN | AstraZeneca PLC | 72% | plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel… |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (v… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions re… |
| BMY | Bristol-Myers Squibb Company | 72% | plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel… |
| BMYMP | Bristol-Myers Squibb Co | 72% | plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from CHRS graph: plans and pension benefit manager… |
| FMS | Fresenius Medical Care AG | 72% | plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel… |
| FMS | Fresenius Medical Care AG | 72% | Reciprocal relationship from FMS graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions re… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from GILD graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers … |
| GILD | Gilead Sciences, Inc. | 72% | plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions re… |
| MRK | Merck & Co., Inc. | 72% | plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from REGN graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from REGN g… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| CHRS-DEBT-8637 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2021-12-31. |
| CHRS-DEBT | Debt stack $54.4M | 90% | Market cache reports total debt of $54.4M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| CHRS-OWNER-BARCLAYS-PLC | BARCLAYS PLC | 90% | 13F overlay lists BARCLAYS PLC as top holder; 156 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 1 | ['customer', 'supplier'] |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| CVS | CVS Health Corporation | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | |
| AMRX | Amneal Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| AVIR | Atea Pharmaceuticals, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| CCCC | C4 Therapeutics, Inc. | 100.00 | 2 | |
| CABA | Cabaletta Bio, Inc. | 100.00 | 2 |